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Abstract: Background: Diabetic Cardiomyopathy (DC) has been defined as a distinct en-
tity characterized by the presence of diastolic or systolic cardiac dysfunction in a diabetic 
patient in the absence of other causes for Cardiomyopathy, such as coronary artery dis-
ease (CAD), hypertension (HTN), or valvular heart disease. Diabetes affects every organ 
in the body and cardiovascular disease accounts for two-thirds of the mortality in the dia-
betic population. Diabetes-related heart disease occurs in the form of coronary artery dis-
ease (CAD), cardiac autonomic neuropathy or DC. The prevalence of cardiac failure is 
high in the diabetic population and DC is a common, but underestimated cause of heart 
failure in diabetes. The strong association between diabetes and heart failure has fueled 
intense human and animal research aimed at identifying the mechanisms underlying dia-
betic myocardial disease. Despite significant progress made, the precise pathogenesis of 
diabetic Cardiomyopathy is yet to be clearly defined. Hyperglycemia, dyslipidemia and 
inflammation are thought to play key roles in the generation of reactive oxygen or nitro-
gen species which are in turn involved.  
Methods: We have reviewed the up-to-date scientific literature addressing these issues. 
Results: The myocardial interstitium undergoes alterations resulting in abnormal contrac-
tile function noted in DC. In the early stages of the disease, diastolic dysfunction is the 
only abnormality, but systolic dysfunction supervenes in the later stages with impaired 
left ventricular ejection fraction. Transmitral Doppler echocardiography is usually used to 
assess diastolic dysfunction, but tissue Doppler Imaging and Cardiac Magnetic Resonance 
Imaging are being increasingly used for early detection of DC. Diabetic patients with mi-
crovascular complications show the strongest association between diabetes and Cardio-
myopathy, an association that parallels the duration and severity of hyperglycemia.  
Conclusion: The management of DC involves improvement in lifestyle, control of glu-
cose and lipid abnormalities, together with treatment of hypertension and CAD, if present. 
Keywords: Cardiomyopathy, diabetes, glucose dysregulation, heart failure, medication.  
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1. INTRODUCTION 
Worldwide, diabetes mellitus is now viewed as an 
epidemic, with cardiovascular disease being the pri-
mary driver of the raised levels of morbidity and mor-
tality in diabetic patients. Besides an increased risk of 
cardiovascular disease in type 1 and type 2 diabetes 
(T2DM) mellitus, this risk may also be evident in pre-
diabetic stages, driven by symptomatology such as im-
pairments in fasting glucose and glucose tolerance, as 
well as wider processes associated with metabolic syn-
drome and obesity. 
Diabetic patients have a high prevalence of heart 
failure or impaired diastolic and systolic cardiac func-
tion subsequent to hypertension, coronary artery dis-
ease and DC [1]. Diabetic patients have a two-fold in-
crease in short- term mortality rate following acute my-
ocardial infarction, compared to non-diabetic patients, 
with the glucose admission profile being a better pre-
dictor of outcome than glycated hemoglobin (HbA1c) 
after a heart attack in diabetic patients [2]. Conse-
quently, the management of cardiovascular risk factors 
in T2DM is of great clinical importance, with wider 
implications driven by the financial and therapeu-
tic/side effect burden of pharmaceutical treatment [3].  
This review focuses on human studies, including 
pathophysiology, diagnostic evaluation and manage-
ment options, whilst highlighting the clinical impor-
tance of early DC identification for the optimization of 
treatment in diabetic patients. 
2. DEFINITION 
The term DC was first introduced over 30 years ago, 
following evidence indicating that diabetes is associ-
ated with a distinct cardiomyopathy, which was inde-
pendent of other known risk factors, such as hyperten-
sion and coronary artery disease. 
Studies using cardiac catheterisation or echocardi-
ography show diastolic dysfunction to be an early indi-
cant of diabetes-driven heart muscle disease, with this 
preceding systolic dysregulation and associated dam-
age. Many of the pathogenetic mechanisms underpin-
ning the risk of DC have been identified, although in 
many cases, their mode of action has still to be clarified 
[4]. Metabolic abnormalities such as hyperglycemia, 
hyperinsulinemia and hyperlipemia may, both directly 
or indirectly, drive the alterations in cardiomyocytes 
that underpin DC pathophysiology, including myocar-
dial fibrosis and myocardial hypertrophy. 
Clinically, metabolic abnormalities are the main 
treatment target. Given that DC is also highly associ-
ated with asymptomatic T2DM patients, it is important 
that screening occurs early, in order to prevent the pro-
gression to chronic heart failure [5].  
3. EPIDEMIOLOGY 
Besides clinical studies, epidemiological data show 
a significant association of T2DM and heart failure. In 
diabetic and non-diabetic patients with symptomatic 
chronic heart failure, HbA1c levels are an independent 
risk factor for cardiovascular-associated death, and 
overall mortality as well as heart failure linked hospi-
talization [6]. A role for HbA1c levels was also indi-
cated in a recent study of 20,985 T1DM patients [7]. 
These authors showed 3% of T1DM patients to be di-
agnosed with heart failure over a 9 yrs follow-up, giv-
ing an incidence of 3.38 events per 1,000 patient/year. 
The hazard ratio for the development of heart failure 
was four-fold higher when HbA1c levels >10.5%, ver-
sus controls with HbA1c <6.5% [7]. 
Hyperglycemia is associated with a change in glu-
cose metabolism, leading to heightened beta-oxidation 
and consequent free fatty acid (FFA) damage, namely 
lipotoxicity, also in the myocardium. Hyperglycemia 
also associates with insulin resistance, activation of the 
renin-angiotensin-aldosterone system, changes in cal-
cium homeostasis and structural changes in the natural 
collagen network. The latter can lead to a less flexible 
matrix, due to advanced glycation end-product (AGE) 
formation, hypertrophy and fibrosis, which all contrib-
ute to the pathophysiology of clinical DC phenotypes. 
Cardiac metabolism is significantly altered in diabetes, 
as indicated by reduced glucose utilization, lower rates 
of lactate oxidation and heightened use of fatty acids. 
Amino acid disturbances are also of potential clinical 
relevance due to quantitative and qualitative changes in 
contractile proteins [8]. 
4. STRUCTURAL/FUNCTIONAL CHANGES IN 
THE DIABETIC HEART 
Significant alterations in the anatomy and the func-
tion of the myocardium underpin the clinico-patholo-
gical consequences of DC. 
Myocardial structure is primarily comprised of 
small cardiomyocytes that are densely packed with mi-
tochondria. The classical phenotype in DC is character-
ized by large areas of fibrosis and a marked reduction 
in sarcomeres. This contrasts to the pathophysiology 
typical of restrictive Cardiomyopathy, where the myo-
cardial structure appears to be characterized by hyper-
trophic cardiomyocytes, collagen deposition between 
cardiomyocytes as well as preserved sarcomeres [9]. In 
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the early stages of DC, pathological alterations occur 
mainly at the level of myocardial interstitium (forma-
tion of AGEs, impaired compliance and ischemia of the 
vasa vasorum), with myocardial contractile dysfunction 
emerging as a consequence of such changes [10]. Later 
abnormalities, including ventricular myocardial hyper-
trophy, fibrosis (interstitial and perivascular) and car-
diac microvascular abnormalities emerge. 
4.1. Left Ventricular Hypertrophy  
Left ventricular hypertrophy (LVH) significantly 
predicts heart failure development, and associated mor-
tality [11]. Hypertension is the main risk factor for 
LVH, although diabetes can also drive such pathologi-
cal remodeling. Echocardiographic studies performed 
in diabetic patients have consistently shown a strong 
association between diabetes, increased LV mass, and 
LVH even in the absence of coexistent hypertension 
[12, 13]. Moreover, obesity itself also portends a raised 
risk of concentric LVH, which is independent of ele-
vated blood pressure [14]. Although the precise 
mechanisms of the hypertrophic response to metabolic 
stress remain to be fully elucidated, LVH has become a 
defined structural characteristic of DC.  
4.2. Diastolic Dysfunction 
DC associated ventricular hypertrophy and fibrosis 
are the primary mediators of diastolic dysfunction. 
Similar to the data on LVH in metabolic disease, 
diabetes is also strongly associated with diastolic dys-
function. In fact, diastolic abnormalities are thought to 
be among the earliest functional manifestations of DC. 
The prevalence of diastolic dysfunction in diabetics 
ranges between 40- 75% [15]. The mechanism of dia-
stolic dysfunction in the diabetic heart may be a conse-
quence of alterations in calcium handling, impaired 
energetics, cardiac lipid accumulation, and/or myocar-
dial fibrosis. Interestingly, the early stages of diastolic 
dysfunction are reversible in diabetics who lose weight 
and normalize their metabolism [16]. This finding im-
plies that the pathogenesis of DC may have a reversible 
phase and emphasizes the importance of early, aggres-
sive lifestyle modification in diabetics with impaired 
myocardial relaxation.  
4.3. Systolic Dysfunction 
Systolic dysfunction is only evident at later DC 
stages. It is unknown whether systolic heart failure is 
the final common pathway of DC or is an alternate 
phenotype determined by the interaction of genetics 
and diabetes in susceptible individuals. It is also impor-
tant to recognize that many diabetics with "normal" 
ejection fraction may actually have impaired systolic 
function when more sophisticated measures, such as 
myocardial strain measurements or tissue doppler, are 
employed [17]. To date, the early stages of systolic 
dysfunction are likely to go unrecognized clinically. 
Cardiac output diminishes progressively with sys-
tolic dysfunction and disease severity. LV systolic ejec-
tion fraction is a reliable indicant of systolic dysfunc-
tion severity and associated heart failure. 
5. FROM THE PATHOGENESIS TO A POSSI-
BLE THERAPY 
DC pathogenesis is complex, typically showing 
changes in lipid metabolism, insulin resistance and mi-
tochondrial function as well as alterations in adipokine 
secretion and signaling. Such factors suggest therapeu-
tic approaches in DC (Table 1) [18]. In summary, the 
most important aspects of DC include: 1) metabolic 
disturbances (insulin resistance, loss of glucose trans-
porter 4, carnitine deficiency, alterations in calcium 
homeostasis and AGE); 2) myocardial fibrosis (in con-
junction with heightened levels of angiotensin II, IGF-
I, pro-inflammatory cytokines, and apoptosis); 3) mi-
croangiopathy (impaired coronary flow reserve, and 
endothelial cell function); 4) cardiac autonomic neu-
ropathy (including denervation as well as changes in 
myocardial catecholamine levels); and 5) mitochon-
drial dysfunction. Each of these alterations suggests a 
possible therapy, as summarized in Fig. (1). In Fig. (2) 
we summarize the difference between the classical and 
other, different phenotypes, in particular, the relative 
importance of DM- related pathophysiological mecha-
nisms for development of DC.  
Table 1. Relationship between pathogenic mechanisms 




Metabolic disturbances Lifestyle modification, hypoglycemic 
drugs and lipid-lowering therapy 
Myocardial fibrosis ACE inhibitors  
Angiotensin II receptor antagonists  
beta adrenoreceptor antagonists  
endothelin-1 receptor antagonists  
antioxidants (magniferin, metal-
lothionein, vitamins C and E)  
Microangiopathy PKC-beta isoform inhibitor  
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Fig. (2). A two-faced disease: restrictive or dilated pheno-
type diabetic Cardiomyopathy  
HFPEF: Heart failure with preserved Ejection Fraction;  
HFREF: Heart failure with reduced Ejection Fraction 
(modified from Petar M. Seferović. Eur. Heart J., 2015).  
5.1. Metabolic Disturbances 
The effects of elevated glucose or altered insulin 
sensitivity on cellular components within the heart has 
significant impacts on cardiac extracellular matrix 
(ECM), contributing to the impact of diabetes in reduc-
ing cardiac function [19]. Factors contributing to such 
alterations in the ECM may include the heightened 
production, lower degradation and chemical modifica-
tion of ECM proteins. The direct or indirect effects of 
high glucose concentrations may be driving such 
changes [20]. In particular high glucose concentration 
levels accelerate collagen types I and III synthesis, 
which an increase in extracellular signal-related kinase 
(ERK)1/2 signalling in cardiac fibroblasts may have an 
important role [21]. Moreover in diabetes, energy pro-
duction shifts from glucose utilization to the beta-
oxidation of FFA, which are supplied to cardiac cells 
from two sources, namely endogenously from the 
lipolysis of cardiac triglyceride stores, or exogenously 
from the blood. 
In a state of impaired /deficient insulin secretion, 
adipose tissue lipolysis is increased, leading to a 
heightened level of circulating FFA. Also, hydrolysis 
of the augmented myocardial triglyceride stores may 
enhance tissue FFA. Regardless of the FFA source, 
their increased utilization can have negative impacts on 
myocardial function, including from the higher oxygen 
requirement required during FFA metabolism, poten-
tially toxic FFA intermediate accumulation intracellu-
larly, and a FFA- driven inhibition of the oxidation of 
glucose oxidation, as well as significant morphological 
changes. Therapies targeting such cardiac metabolic 
alterations in the early stages of diabetes would then 
 
Fig. (1). Summary of the pathogenic mechanisms of diabetic Cardiomyopathy. 
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have the potential to delay the onset of more permanent 
sequelae [22]. The exposure to high levels of circulat-
ing FFA has been proposed to be a major contributor to 
DC [23]. Data in women classed as overweight or 
obese, indicate insulin resistance to be linked to height-
ened myocardial triglyceride content and cardiac re-
modelling as well as lower diastolic function [24]. 
High density lipoprotein (HDL) cholesterol may in-
directly modulate DC, via the regulation of metabolic 
triggers, such as hyperglycemia, hyperinsulinemia, and 
hyperlipidemia. Such factors can drive DC associated 
cellular changes by a variety of processes, as detailed 
above, including immune-inflammatory processes, and 
Ca
2+
 handling, as well as oxidative and nitrosative 
stress, and endothelial dysregulation [25]. Disturbed 
glucose metabolism can lead to AGE formation, which 
can associate with lipofuscin, and is linked premature 
cell ageing. A recent investigation assessed heart fail-
ure and AGE formation in patients with or without 
T2DM. The amount of AGE in cardiomyocytes in-
creases significantly, both in diabetes and heart failure, 
with a staining pattern that is typical for each condition 
[26]. As previously indicated oxidative stress has a sig-
nificant impact on the pathogenesis of DC, suggesting 
the potential utility of antioxidant therapy [27]. The 
inflammation associated transcription factor, nuclear 
factor-kappa B (NF-kB), is an important driver of 
many of the changes occurring across an array of 
medical conditions, including different heart diseases. 
As such, NF-kB may be a crucial driver of many of the 
processes linked to DC, including oxidative stress and 
inflammation [28]. The post-translation attachment of 
O -linked N-acetylglucosamine, or O-GlcNAc, to ser-
ine and threonine residues within both nuclear and cy-
toplasmic proteins, is achieving growing recognition as 
an important regulator of an array of cellular processes. 
The heightened and sustained enhancement of O-
GlcNAc levels are associated with glucose toxicity and 
insulin resistance. Increased O-GlcNAc levels could 
contribute to the negative impacts of diabetes on the 
heart, including impairments in contractility and cal-
cium handling, as well as stress responses. As recent 
data indicates that O-GlcNAc modulates epigenetic 
processes, this could be another ubiquitious mechanism 
that may contribute to diabetes-driven changes in DC 
[29]. 
No single pharmaceutical can treat DC, with man-
agement thought to necessitate a variety of approaches, 
including: lifestyle modification; glucose control (insu-
lin, sulfonylureas, thiazolidinediones, alpha glucosi-
dase inhibitors, biguanides, meglitinides and dipeptidyl 
peptidase 4 (DPP-4) inhibitors); GLP -1 analogs; cal-
cium channel blockers (amlodipine, verapamil); ACE 
inhibitors (captopril, enalapril); angiotensin II receptor 
antagonists (losartan, olmesartan); endothelin-1 recep-
tor antagonists (bosentan, tezosentan); beta adrenore-
ceptor antagonists (acebutolol, carvedilol); peptides 
(adrenomedullin); antioxidants (methalothionein, alpha 
tocopherol, alpha lipoic acid); and antihyperlipidemic 
drugs (fenofibrate, simvastatin, ezetimibe [30].  
5.2. Microangiopathy 
Hemodynamic and structural changes, such as capil-
lary basement membrane thickening, and interstitial 
fibrosis as well as myocyte hypertrophy and cellular 
necrosis can arise as a result of changes in several fac-
tors including vasoactive molecules, which may be 
crucial in mediating the deficits in structure and func-
tion during the early and late disease stages [31]. 
Moreover, diabetes affects the heart via a quantifiable 
increase in chamber visco-elasticity rather than an in-
crease in chamber stiffness and the phenotypic charac-
terization of DC is facilitated by diastolic function as-
sessment [32]. A new role of DPP4 in micro- and 
macro-vascular vessels is emerging [33, 34]. 
Diastolic dysfunction and microvascular function 
may be intimately linked, although the relationship be-
tween endothelial dysfunction, profibrotic connective 
tissue growth factor and refined measures of diastolic 
dysfunction is not strong, suggesting that other factors 
may be crucial to the early pathogenesis of subclinical 
cardiac diastolic dysfunction common in T2DM [35]. 
Diabetic patients with microangiopathy have impair-
ments in left ventricle functioning, whereas those with 
uncomplicated diabetes have normal function. This 
suggests the existence of a specific subtype of DC with 
microangiopathy, but not with a metabolic defect. The 
linking of microangiopathy and suboptimal left ventri-
cle functioning may underpin the high immediate mor-
tality and the heightened incidence of cardiogenic shock 
and congestive heart failure that is evident after myo-
cardial infarction in diabetic patients [36]. Although 
requiring further investigation, such studies may sug-
gest a subclinical DC that arises from small-vessel dis-
ease [37]. 
Human diabetes mellitus shows evidence of de-
creased cardiac myofilament functioning, which, cou-
pled to depressed cardiac myofilament Ca
2+
 respon-
siveness, may underpin the suboptimal ventricle func-
tioning that is characteristic of DC [38]. Recent data 
indicates that diabetes depresses AMP-activated pro-
tein kinase (AMPK) activity, thereby promoting the 
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interaction of BECN1 and the anti-apoptotic protein, 
BCL2. Concurrently, diabetes increases the risk of car-
diomyocyte apoptosis, whilst also suppressing cardiac 
autophagy. AMPK activation leads to MAPK8 phos-
phorylation, in turn driving BCL2 phosphorylation and 
is dissociation from the BECN1-BCL2 complex. There-
fore AMPK, via BCL2, restores cardiac autophagy, 
protects against cardiac apoptotic processes, thereby 
better optimizing cardiac structure and function. 
The dissociation of BCL2 from BECN1 through the 
activation of MAPK8- BCL2 signalling may be impor-
tant in driving the processes through which AMPK ac-
tivation can restore autophagy, whilst protecting agai-
nst cardiac apoptosis and preventing DC [39].  
Protein kinase C (PKC) is linked to alterations in 
the vasculature, including increasing permeability, ex-
tracellular matrix synthesis, contractility, cell growth, 
apoptosis, angiogenesis and leukocyte adhesion, as well 
as both cytokine activation and inhibition. Different 
PKC isoforms (PKC-alpha, -beta1/2, and PKC-delta) 
underpin such perturbations in vascular cell homeosta-
sis, including in large as well as small vessels. In clini-
cal trials, a PKC-beta isoform inhibitor has shown posi-
tive effects in diabetic non proliferative retinopathy and 
nephropathy, as well as in endothelial dysfunction [40]. 
The selective inhibition of PKC βII represents an effec-
tive approach for treating microvascular complications 
[41].  
5.3. Myocardial Fibrosis 
A number of factors contribute to the dysregulation 
of cardiac insulin and metabolic dysregulation, includ-
ing: systemic insulin resistance, adipokine secretion 
dysregulation, hyperinsulinemia, raised levels of circu-
lating inflammatory mediators, aberrant renin angio-
tensin aldosterone system activation and increased oxi-
dative stress, which all contribute to diastolic dysfunc-
tion. Suboptimal calcium homeostasis and endothelial 
cell dysregulation as well as endoplasmic reticular 
stress may also contribute to cardiomyocyte fibrosis 
and diastolic dysfunction [42]. Many investigators have 
proposed that inhibiting the renin-angiotensin-aldoste-
rone and sympathetic nervous systems may have clini-
cal utility in DC patients. The efficacy of angiotensin II 
and aldosterone blockade has been proposed to be me-
diated, at least in part, by aldosterone blockade leading 
to the down-regulation of the activity of the Na(+)/H(+) 
exchanger 1. Such a role for the regulation of ion chan-
nels in DC requires further investigation [43]. Apopto-
sis is crucial to the pathophysiology of most medical 
conditions, including DC, by driving the death of ter-
minally differentiated cardiomyocytes. The efficacy of 
apoptosis inhibition in preventing the development of 
heart failure has been shown in many studies. We now 
review the role of apoptosis across cardiovascular dis-
eases, especially its role in the molecular processes 
driving cardiomyocyte death [44]. 
The FKHR gene product, FoxO1, belongs to the 
forkhead box family of transcription factors, and con-
tributes to the regulating of metabolism, cell prolifera-
tion, the oxidative stress response and immune homeo-
stasis as well as having a role in cell death processes. 
Given that FoxO1 has cardio-protective effects against 
an array of stressors, it has been the subject of investi-
gation in regard to DC. The cardiac tissue- specific de-
letion of FoxO1 affords protection to the heart against 
Cardiomyopathy, whilst FoxO1 down-regulation in 
endothelial cells may afford protection against athero-
sclerotic plaques [45]. Future studies will have to clar-
ify the role of FoxO1 in the etiology, course and man-
agement of DC. Two important pathways are involved 
in development of cardiac fibrosis: the renin-angio-
tensin system and AGE and its receptor, RAGE. Car-
diac fibrosis is an important component of DC, with a 
recent study suggesting a possible crosstalk between 
the RAS and AGE/RAGE pathway in the etiology of 
cardiac fibrosis in diabetes [46]. There is a growing 
appreciation of the multitude of roles and impacts of 
the renin-angiotensin-aldosterone system, including in 
the regulation of diabetes [47]. Other processes may 
also be relevant, with data indicating that endothelin-1 
and Na + /H + exchanger -1 (NHE-1) can lead to car-
diomyocyte hypertrophy via the activation of the MAPK 
activation pathways, suggesting a role in DC [48]. 
More recently, it has been shown that the role of 
AMPK extends to several non-metabolic effects related 
to other cardiac diseases, suggesting that AMPK could 
play both physiological and pathophysiological roles in 
the regulation of cardiac metabolism and wider heart 
functioning [49]. Matricellular proteins are induced 
following cardiac injury and the process of cardiac re-
modeling heart, where they act to regulate inflamma-
tory, reparative, fibrotic and angiogenic processes. 
Thrombospondin (TSP)-1, -2, and -4, tenascin-C and - 
X secreted protein acidic and rich in cysteine (SPARC), 
periostin, osteopontin, and the CCN family members, 
such as CCN1 and CCN2/connective tissue growth fac-
tor, are important regulators of an array of cardiac con-
ditions and pathophysiological processes, including DC 
[50]. Both ramipril and telmisartan, used in the treat-
ment of hypertension, improve echocardiographic left 
ventricular diastolic indices, whilst lowering plasma 
brain natriuretic peptide (BNP) levels in patients with 
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diabetes, especially when used in combination [51]. An 
array of other medications and factors show evidence 
of decreasing interstitial fibrosis and improving heart 
functioning in DC, including beta- adrenoreceptor an-
tagonists, ACE inhibitors, Bonestan, an antagonist at 
the endothelin-receptor antagonist, and adrenomedullin, 
as well as hormones, such as (insulin, IGF-1, and anti-
oxidants, including vitamins C and E, magniferin and 
metallothionein [52]. Clinical trials are necessary to 
clarify the utility of such data [53]. Other data has im-
plicated a role for immune cells in DC, with myeloid 
dendritic cells being upregulated in the course of insu-
lin-resistance and obesity, which may modulate the 
pathological vascular remodeling evident in DC [54]. 
5.4. Cardiac Autonomic Neuropathy 
Autonomic dysfunction, in the form of cardiovascu-
lar autonomic neuropathy, is not uncommon in diabetes 
mellitus and is proposed to be associated with heart 
rate control dysregulation as well as abnormalities in 
vascular dynamics. Moreover, cardiac autonomic neu-
ropathy is linked to left ventricular diastolic dysfunc-
tion (LVDD) in T2DM patients with no clinical mani-
festations of heart disease. DC can be detected by 24hr 
ECG monitoring and echocardiography, including in 
the early stages of DC and is recommended as an as-
sessment in all patients at risk [55]. The diastolic dys-
function of T2DM associates with sympathetic integ-
rity regional markers as well as autonomic neuropathy 
clinical markers [56]. 
LVDD and cardiac autonomic neuropathy (CAN) 
may be present in otherwise well-managed T2DM pa-
tients. The parameters defining LVDD and CAN may 
useful in better identifying DC, and therefore could 
prove to be good prognostic indicators, as in nondia-
betic populations [57].  
5.5. Mitochondrial Dysfunction  
Evidence indicates that myocardial metabolism is 
significantly changed in diabetes, which is thought to 
contribute to contractile dysfunction as well as ven-
tricular failure. Mitochondria are crucial to alterations 
in metabolism, and have a role in DC recent data [58]. 
Cardiomyocytes are packed with mitochondria, so 
any progressive decline in mitochondrial functioning 
will contribute to heart senescence. Suboptimal mito-
chondrial functioning leads to lower levels of ATP 
production and higher levels of ROS, with both 
changes contributing to an increased likelihood of 
apoptosis. Dysfunctional mitochondria also need to be 
removed in order to optimize cell functioning, which is 
achieved by macroautophagy, a process that is less ef-
ficient with advancing age. As such, the activity, 
movement and disposal of mitochondria are important 
in heart senescence as well as age-related cardiovascu-
lar diseases more widely. 
Interventions that inhibit cardiac ageing, will lead to 
improvements in mitochondria functioning as well as 
macroautophagy and the oxidative/antioxidative bal-
ance, suggesting impacts on key processes of cellular 
functioning and important therapeutic targets in DC 
[59].  
5.6. Other Possible Future Therapy  
Zinc homeostasis is as a growing area of research in 
cardiovascular disorders. Zinc is important in the 
maintenance of cellular structure and physiology. As 
such, zinc replenishment can improve cardiac function 
as well as prevent any further damage [60].  
Another candidate is represented by cardiac ryano-
dine receptors (RyR2s) that act on the redox regulation 
of the cardiac Ca(2+) transport systems and could have 
a role in redox regulation of pathological cardiac dys-
regulation that is present in diabetes [61]. 
Diabetes associated cardiac fibrosis is linked to the 
endothelial-to-mesenchymal transition process, which 
is positively modulated by endothelin 1 (ET-1). This 
suggests that the targeting ET-1 from endothelial cells 
may have treatment efficacy in DC [62].  
Hyperglycemia can contribute to raising levels of 
the pro-inflammatory cytokine, macrophage migration 
inhibitory factor (MIF), which increases the likelihood 
of developing Cardiomyopathy in T2DM patients, with 
increased levels of MIF also contributing to wider 
symptomatology. The elevated levels of cardiac dys-
function in T2DM patients [63]. The identification of 
the mechanism underlying such hyperglycemic-driven 
effects should aid in the search for new treatment tar-
gets in DC [64].  
In addition to life style modifications, and well re-
searched treatments, such as ACE inhibitors, beta-
blockers and angiotensin II receptor antagonists, 
trimetazidine may be usefully administered to patients 
showing impaired glucose tolerance and/or in the early 
course of T2DM. This is proposed, given that trimetaz-
idine can act as a metabolic switch, leading to the pref-
erential use of glucose over FFA as the metabolic sub-
strate in cardiomyocytes [65]. Trimetazidine may also 
lower the prevalence of heart failure as increase long-
term survival in T2DM patients, in part via the early 
normalization of the substrate of myocardial metabo-
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lism [66]. Further investigation on the potential effi-
cacy of trimetazidine on idiopathic dilated Cardiomy-
opathy in diabetic patients is required. 
Galanin can modulate glucose homeostasis and car-
bohydrate metabolism in cardiomyocytes as well as in 
skeletal muscles. Galanin also increases the expression 
levels and translocation of the glucose transporter 4 
(GLUT4) in insulin-sensitive cells, thereby lowering 
levels of insulin resistance. Such data suggests that en-
dogenous galanin is likely to positively regulate the 
diabetic heart [67]. 
A recent study in a DC model, investigated the car-
dio-reparative properties of sildenafil, which is well 
researched selective phosphodiesterase type 5 inhibitor. 
Given that an early aspects of DC include LV concen-
tric hypertrophy in association with alterations in the 
dynamics of myocardial contraction, it is of note that 
the chronic inhibition of phosphodiesterase type 5, at 
such an early stage, inhhibits remodelling, with conse-
quent benefits in icardiac kinetics as well as circulating 
markers. This effect seems to be mediated via direct 
impacts on intramyocardial activity, being independent 
of vasodilatory and endothelial cell regulation [68]. 
A growing body of data indicates a role for the fatty 
acid transporter and scavenger receptor, CD36, in the 
etiology of insulin resistance and the development of 
T2DM associated cardiovascular problems. The shift of 
CD36 to the plasma membrane from intracellular stores 
occurs early in the heart during the course of diet in-
duced obesity and the development of insulin resis-
tance. This CD36 shift increases the rate of fatty acid 
uptake, leading to fatty acid incorporation into triacyl-
glycerol stores and consequently to lipid intermediates, 
with these changes compromising insulin-induced 
GLUT4 recruitment. Such data indicates that CD36 
requires further investigation, including as a therapeu-
tic target in the redirecting of body fatty acid fluxes 
[69]. 
6. DIAGNOSIS 
Most DC cases may be subclinical, with no evident 
overt symptoms, such as changes in left ventricular 
mass, wall thickness and cardiac cavity dimensions. 
However, Cardiomyopathy-related abnormalities are 
functionally expressed and can be detected by echocar-
diography. 
The initial DC stages show a deterioration in longi-
tudinal systolic function that is compensated by an ele-
vation in the radial function. Diastolic dysfunction is 
also an initial sign. A shift from functional to morpho-
logical changes occurs as DC progresses, including left 
ventricular concentric hypertrophy and fibrosis, as in-
dicated above. End stage DC characteristics include a 
reduction in the ejection fraction as well as ventricular 
dilatation, whilst the very late stages can often mimic 
dilatative Cardiomyopathy [70]. The analysis of dia-
betic heart disease with pulsed Doppler techniques in 
order to assess the systolic and diastolic functioning of 
the left ventricle, is important to investigate in all indi-
cated patients, as an asymptomatic patient can show 
indications of diastolic dysfunction that is treatable 
[71]. Early stage DC can also be indicated by Doppler 
imaging, which is clinically important at an early stage 
where left ventricular diastolic dysfunction, without 
any obvious clinical symptomatology [72]. As indi-
cated above, diabetes leads to myocardial damage lead-
ing to diastolic dysfunction, prior to any systolic dys-
function.  
Diastolic dysfunction significantly correlates with 
disease duration, as well as glycemic levels and the 
patients treatment history. Echocardiography is a rela-
tively inexpensive investigative tool that detects struc-
tural and functional cardiac abnormalities. It should 
also be noted that systolic dysfunction can be detected 
by the standard echocardiography in the relatively early 
stages. 
Transmitral Doppler (Mitral valve blood flow 
measured by pulsed wave Doppler) is the standard pro-
cedure for the assessment of ventricular diastolic func-
tion [73]. Transmitral Doppler measures a number of 
variables, including: the early (E-wave) and late (A- 
wave) ventricular filling waves, providing an E/A ratio; 
the isovolumetric relaxation time (IVRT); the E-wave 
deceleration time (EDT); the E-wave peak velocity (E); 
and the A-wave duration (A-dur). Diastolic function, 
on the basis of such measures, can be categorized ac-
cordingly: (1) normal pattern; (2) grade I (impaired 
relaxation); (3) grade II (pseudonormal pattern); and 
(4) grade III (restrictive pattern) [74]. Grade I diastolic 
dysfunction patients show an E/A ratio < 1, arising 
from a lower early and raised late diastolic flows [75]. 
This assessment is routinely administered to diabetic 
patients, prior to the reporting of any cardiac symptoms 
[76].  
Some authors have suggested that plasma BNP may 
be utilized as an alternative screening tool for the iden-
tification of subclinical LV dysfunction. However, 
other alternative screening approaches, such as BNP, 
are not sufficiently sensitive in the case of subclinical 
dysfunction presentations [77]. Modern tissue Doppler 
applications have greater sensitivity for diagnosing dia-
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stolic dysfunction, when compared to pulsed Doppler 
(63% vs. 50%) [78] and they may detect abnormalities 
of diastolic function when the patient is still asympto-
matic and their systolic function is normal. Tissue 
Doppler imaging (TDI) measures myocardial tissue 
velocities over the cardiac cycle, allowing the quantita-
tive assessment of myocardial global and regional sys-
tolic and diastolic functions [79, 80]. TDI allows myo-
cardial tissue velocities measurement in the longitudi-
nal direction, as well as peak early diastolic myocardial 
velocity (E0), which is a reflection of global left ven-
tricular diastolic function [81]. 
As well as such conventional assessment tools, 
newer approaches to the diagnostic measurement of 
myocardial fibrosis and cardiac metabolic dysfunction 
include magnetic resonance imaging (MRI) and spec-
troscopy plus contrast agents. When complemented 
with serum biomarkers such strategies provide a valu-
able indication of diabetes-driven alterations in cardiac 
structure and function, including the very early stages 
of disease manifestation [82]. Furthermore, MRI is 
gaining popularity as a valuable diagnostic tool for 
myocardial disorders [83, 84], including by demon-
strating the presence of fatty or fibrosis infiltrates in the 
hypertrophied myocardium, as well as a notable altera-
tion in the myocardial geometry and ventricular mass. 
Generally, left ventricular diastolic and systolic func-
tional abnormalities have been detected in 21% and 
15% of the asymptomatic diabetic patients, respec-
tively [85]. Cardiac MRI also has utility in the detec-
tion of diastolic dysfunction and myocardial steatosis 
[86].  
Cardiac MRI, using different radionuclides, and 
positron emission tomography (PET) clearly have util-
ity in the diagnosis of DC. The cutting edge of diagnos-
tic imaging in diabetes, includes: 1) PET, which can 
measure resting and stress blood flow as well as coro-
nary flow reserve; 2) radionuclide procedures that 
measure aerobic and anaerobic cardiac metabolic activ-
ity; and 3) cardiac neurotransmission imaging, which is 
useful in the diagnosis and evaluation of autonomic 
neuropathy [87].  
As indicated above, both metabolic and vascular 
disturbances contribute to DC. The correlation among 
myocardial diastolic dysfunction, metabolic distur-
bances, and post-contrast T1 values supports the role of 
diffuse myocardial fibrosis in the biological underpin-
nings of early DC [88]. Fig. (3) shows possible diag-
nostic criteria for the diagnosis of the two DC subtypes.  
7. IS IT POSSIBLE TO PREVENT DC? 
Some studies have proposed possible strategies for 
preventing DC, although we are far from being able to 
identify patients at risk of developing DC. Only study 
that has evaluated the DC predictors, showing that 
apolipoprotein 1 has predictive utility [87-89]. 
Cardiovascular complications are major contributors 
to the heightened mortality and morbidity levels in dia-
betic patients, with epigenetic changes, as a conse-
quence of environmental factors and their interactions 
with genetic factors, proposed to play an important role 
in disease susceptibility. Epigenetic mechanisms, in-
cluding DNA methylation, microRNA, chromatin re-
modelling and histone modifications are powerful regu-
 
Fig. (3). Possible diagnostic criteria for the two subtypes of diabetic Cardiomyopathy (modified from Petar M. Seferović. Eur 
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lators of gene expression, with relevance to the patho-
physiology of DC [90, 91]. MicroRNAs are a novel 
group of non-coding small RNAs that co-ordinate gene 
activity patterns, being increasingly recognized to have 
a significant role in a wide array of physiological and 
pathophysiological processes. Recent studies indicate 
that microRNAs have a critical role in cardiovascular 
complications, as well as having utility as blood bio-
markers [92-94].  
A recent study showed that lower eNOS expression 
can predispose to impaired glucose homeostasis, with 
consequences for cardiovascular diseases [95], whilst 
other researchers have suggested adipokines as poten-
tial novel predictors of cardiovascular diseases, and 
therefore with potential to treat prior to obvious symp-
tomatology [96]. 
8. ORAL GLUCOSE-LOWERING THERAPIES: 
INFLUENCE IN CARDIOVASCULAR MORBID-
ITY AND MORTALITY 
An important year for cardiac dysregulation in dia-
betes was 2013 for two reasons: 1) a major revision of 
the clinical guidelines for heart failure with comorbid 
diabetes was published [97]; and 2) there was an unex-
pected increase in heart failure incidence in the clinical 
trials of saxagliptin versus placebo [98]. A large scale 
clinical trial in 2008 suggested intensive glycemic con-
trol increased, rather than decreased, cardiovascular 
mortality in patients with diabetes [99]. In the same 
year, the Food and Drug Administration gave their ap-
proval of oral glucose-lowering therapies for T2DM, 
with an approval that was contingent on an effective 
reduction in HbA1c reduction followed by a postmar-
keting cardiovascular outcomes trial that had prede-
fined end points, with relatively longer follow-up peri-
ods, and tested in a sample of patients at high risk, with 
efficacy criteria requiring a demonstration of “noninfe-
riority” to placebo. Incretin-based therapies were the 
initial drugs evaluated under this new guidance policy 
[100]. The cardiovascular side effects of anti-diabetic 
drugs are believed to be an important reason for the 
increased heart failure risk in intensive glycemic con-
trol patients. Most of the currently available oral anti-
diabetic drugs have more or less shown adverse cardio-
vascular side effects. In addition to DPP4 inhibitors, 
commonly used oral anti-diabetes agents, include 
biguanides, thiazolidinediones, and sulfonylureas 
[101], with the biguanide, Metformin, contraindicated 
in diabetic patients with heart failure, likely from an 
increased risk of lactic acidosis. However, later studies 
demonstrated that metformin is safe and may be linked 
to a lower morbidity and mortality in diabetic patients 
with established heart failure, when compared to other 
anti-diabetic therapy.  
However, it should be noted that no placebo-
controlled large scale trials on heart failure are avail-
able [102, 103], with the thiazolidinediones, such as 
rosiglitazone and pioglitazone, linked to increased 
heart failure and fluid retention [104]. Sulfonylureas 
seem to produce a dose-dependent and time-dependent 
increase in the risk of heart failure, whilst clinical evi-
dence has shown the 2
nd
 generation of sulphonylureas 
(glipizide, gliquidone, glimepiride, glibenclamide, and 
gliclazide) to have an increased the risk of developing 
congestive heart failure by 18%, compared to metfomin 
[105]. In another study following 4,902 diabetic 
women for a mean duration of 11 years, Li et al. re-
ported that sulfonylurea increased the risks of coronary 
heart disease [106]. 
In contrast, preclinical data on GLP-1 agonists and 
DPP4 inhibitors, indicate that they promote nonglyce-
mic-mediated cardioprotective effects. To date, 3 DPP4 
inhibitors (saxagliptin [107], alogliptin [108], and sita-
gliptin [109] and one GLP-1 agonist (lixisenatide 
[110], published data on cardiovascular outcomes. 
Their results have questioned the cardiovascular safety, 
especially in regards to heart failure from the DPP4 
inhibitors class, following the completion of two large 
clinical trials [106, 107]. While both trials showed no 
significant increase risk in composite cardiovascular 
outcome measures, the SAVOR-TIMI 53 trial reported 
a 27% rise in hospitalization for heart failure, but not in 
heart failure mortality. 
There have been two other large scale trials, one on 
DPP4 inhibitor sitagliptin (TECOS) and one on GLP-
1R agonist lixisenatide (ELIXA), which reported no 
excess heart failure risk. Future studies will be required 
to clarify the implications of these studies.  
Studies in humans confirmed the vasodilatory effect 
of GLP-1. GLP-1 analogs are also able to reduce blood 
pressure by increasing urinary sodium excretion, pro-
moting atrial natriuretic peptide (ANP) release from the 
atrium, and relaxing vascular smooth muscle cells. Ac-
tivation of GLP-1R in the central nervous system in-
duces satiety and thus reduces body weight and cardio-
vascular risk. In addition to enhancing GLP-1 effects, 
DPP4 inhibitors also increases stromal cell-derived fac-
tor (SDF)-1, a chemoattractant for many types of he-
matopoietic cells, including cardiac stem cells, endo-
thelial progenitor cells, and mesenchymal stem cells. 
Preservation of SDF-1 by DPP4 inhibition enhances 
chemotaxis and the repopulation ability of hema-
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topoietic progenitor cells and stem cells, increasing the 
neovascularization of injured tissues [111]. A further 
prospective study on heart failure risk induced by anti-
diabetic medications are under consideration for the 
incidence of hypoglycemia, heart failure, and cardiac 
function [112].  
Empagliflozin iselectively inhibits the sodium-
glucose cotransporter 2 (SGLT2), and is used in the 
management of T2DM. By inhibiting SGLT2, empagli-
flozin reduces the reabsorption of glucose in the kidney 
and therefore increases glucose excretion in the urine. 
As well as lowering hyperglycemia, empagliflozin is 
associated with a number of other changes, including 
osmotic diuresis, lower body weight and blood pressure 
without raised heart rate, whilst it also has favourable 
impacts on markers of arterial stiffness and vascular 
resistance and albuminuria, as well as serum uric acid 
[113]. In the EMPA-REG OUTCOME trial, empagli-
flozin lowered the primary composite outcome on car-
diovascular death as well as lowering non-fatal myo-
cardial infarction and non-fatal stroke, including lower-
ing cardiovascular death by 38%, hospitalization for 
heart failure by 35%, and overall mortality by 32%, 
versus placebo, in T2DM patients with a high cardio-
vascular risk over a median time period of 2.6 years. 
The effect of empagliflozin on heart failure hospi-
talization, cardiovascular death and on all-cause hospi-
talization was present early in the trial, being sustained 
throughout. This indicates a non-atherosclerosis related 
effect, with efficacy that requires clarification in future 
studies [114]. 
Recently, Ferranini [115] hypothesized that SGLT2 
inhibitor-driven mild, persistent hyperketonemia, b-
hydroxybutyrate is readily taken up by the heart, where 
it is oxidized in preference to fatty acids. Such an al-
teration in fuel selection improves the transduction of 
oxygen consumption and consequently mitochondrial 
functioning. In addition, the hemoconcentration follow-
ing SGLT2 inhibition increases oxygen release to the 
tissues. These mechanisms may interact with the other 
SGLT2-induced changes, such as lowering blood pres-
sure and increasing diuresis that would be expected to 
afford some cardioprotection, as indicated in the 
EMPA-REG OUTCOME trial. 
Given the microvascular benefit of improved gly-
cemic control, the identification of diabetic medication 
with a safe cardiovascular profile and which signifi-
cantly lowers glucose is still an unfulfilled clinical need 
and target, requiring future investigation and long-term 
outcome studies [100]. 
CONCLUSION 
These recent insights provide important additions to 
our knowledge regarding DC, although much remains 
to be discovered. In particular, specific pharmacothera-
pies for DC are required that reduce the raised levels of 
cardiovascular morbidity and mortality in diabetic pa-
tients. It is important to detect DC in the early stages as 
well as research of DC in asymptomatic diabetic pa-
tients, which may help to stop the progression to heart 
failure. It is clear that further work is required on the 
biochemical underpinnings in different cell types that 
produce a bias toward DC symptomatology, which may 
provide more targeted pharmaceutical treatments. 
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